Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | GAA | P10253 | 11/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14260717 | 0.82 | ALDH1A1 (0.57) | ALDH1A1GAASMN1; SMN2RAB9ARECQL | |
| SCHEMBL13754002 | 0.81 | NPC1 (0.59) | ALDH1A1GAASMN1; SMN2RAB9ARECQL | |
| SCHEMBL19634835 | 0.80 | RAB9A (0.56) | ALDH1A1GAASMN1; SMN2MAPTRAB9A | |
| SCHEMBL19113898 | 0.79 | RAB9A (0.51) | ALDH1A1GAASMN1; SMN2MAPTRAB9A | |
| SCHEMBL9328693 | 0.78 | RAB9A (0.50) | ALDH1A1GAASMN1; SMN2RAB9ARECQL | |
| SCHEMBL15296687 | 0.78 | NPC1 (0.48) | ALDH1A1GAASMN1; SMN2MAPTRAB9A | |
| SCHEMBL12669759 | 0.77 | RAB9A (0.53) | ALDH1A1GAASMN1; SMN2RAB9ARECQL | |
| SCHEMBL1477812 | 0.77 | RAB9A (0.47) | ALDH1A1GAASMN1; SMN2MAPTRAB9A | |
| SCHEMBL3344131 | 0.77 | CNR1 (0.47) | ALDH1A1GAASMN1; SMN2MAPTRAB9A | |
| SCHEMBL9529702 | 0.77 | CTSV (0.51) | ALDH1A1GAASMN1; SMN2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053463-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-21 | — | — | US | disclosed |
| EP-1638938-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECH INC (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2325181-B1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2017-03-29 | — | — | EP | disclosed |
| EP-3006425-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | Siga Technologies, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20160016962-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-21 | — | — | US | disclosed |
| EP-2970304-A1 | P2X7 MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| US-20150290190-A1 | [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-15 | — | — | US | disclosed |
| CN-104758281-A | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES INC | 2015-07-08 | — | — | CN | disclosed |
| US-9045418-B2 | Compounds, compositions and methods for treatment and prevention of Orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9040534-B2 | [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | disclosed |
| US-20080004452-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1869017-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| US-20070287735-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007125061-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125061-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| US-20060235051-A1 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2006-10-19 | — | — | US | disclosed |
| WO-2006108701-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| EP-1638938-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | Siga Technologies, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20060008862-A1 | Real time methylumbelliferone-based assay | THE HOSPITAL FOR SICK CHILDREN | 2006-01-12 | — | — | US | disclosed |
| WO-2004112718-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287735-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | ALDH1A1 1119/4885GAA 239/4885SMN1; SMN2 3328/4885 |
| US-20160016962-A1 | P2X7 MODULATORS | P2RX5, P2RX1, P2RX7 | ALDH1A1 2378/4885GAA 1343/4885SMN1; SMN2 902/4885 |
| US-20060235051-A1 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | ALDH1A1 1899/4885GAA 141/4885SMN1; SMN2 2395/4885 |
| US-20150290190-A1 | [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS P2X7 MODULATORS | P2RX7, P2RX5, P2RX2 | ALDH1A1 871/4885GAA 3669/4885SMN1; SMN2 4396/4885 |
| US-20080004452-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | ALDH1A1 1119/4885GAA 239/4885SMN1; SMN2 3328/4885 |
| US-10053463-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | HTR5A, P2RX5, P2RX3 | ALDH1A1 2966/4885GAA 2110/4885SMN1; SMN2 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.